These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 9791142)

  • 41. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Meibohm A; Condra JH; Valentine FT; McMahon D; Gonzalez C; Jonas L; Emini EA; Chodakewitz JA; Isaacs R; Richman DD
    Ann Intern Med; 2000 Jul; 133(1):35-9. PubMed ID: 10877738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.
    Garcia PM; Kalish LA; Pitt J; Minkoff H; Quinn TC; Burchett SK; Kornegay J; Jackson B; Moye J; Hanson C; Zorrilla C; Lew JF
    N Engl J Med; 1999 Aug; 341(6):394-402. PubMed ID: 10432324
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
    Havlir DV; Hellmann NS; Petropoulos CJ; Whitcomb JM; Collier AC; Hirsch MS; Tebas P; Sommadossi JP; Richman DD
    JAMA; 2000 Jan; 283(2):229-34. PubMed ID: 10634339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
    Descamps D; Flandre P; Joly V; Meiffrédy V; Peytavin G; Izopet J; Tamalet C; Zeng AF; Harel M; Lastère S; Aboulker JP; Yéni P; Brun-Vézinet F;
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):464-71. PubMed ID: 12473833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.
    Gulick RM; Meibohm A; Havlir D; Eron JJ; Mosley A; Chodakewitz JA; Isaacs R; Gonzalez C; McMahon D; Richman DD; Robertson M; Mellors JW
    AIDS; 2003 Nov; 17(16):2345-9. PubMed ID: 14571186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.
    Tashima K; Staszewski S; Nelson M; Rachlis A; Skiest D; Stryker R; Bessen L; Overfield S; Ruiz N; Wirtz V
    AIDS; 2008 Jan; 22(2):275-9. PubMed ID: 18097230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
    Zhang L; Ramratnam B; Tenner-Racz K; He Y; Vesanen M; Lewin S; Talal A; Racz P; Perelson AS; Korber BT; Markowitz M; Ho DD
    N Engl J Med; 1999 May; 340(21):1605-13. PubMed ID: 10341272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
    N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
    Maggiolo F; Callegaro A; Arici C; Quinzan G; Gregis G; Ripamonti D; Tebaldi A; Goglio A; Suter F
    Antivir Ther; 2003 Apr; 8(2):121-6. PubMed ID: 12741624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
    Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
    Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Summaries for patients. Predictors of outcomes in patients with HIV infection treated with indinavir, zidovudine, and lamivudine.
    Ann Intern Med; 2001 Dec; 135(11):S-59. PubMed ID: 11759663
    [No Abstract]   [Full Text] [Related]  

  • 55. Raltegravir with optimized background therapy for resistant HIV-1 infection.
    Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
    N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A controlled trial of zidovudine in primary human immunodeficiency virus infection.
    Kinloch-De Loës S; Hirschel BJ; Hoen B; Cooper DA; Tindall B; Carr A; Saurat JH; Clumeck N; Lazzarin A; Mathiesen L
    N Engl J Med; 1995 Aug; 333(7):408-13. PubMed ID: 7616989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.
    Mandelbrot L; Landreau-Mascaro A; Rekacewicz C; Berrebi A; Bénifla JL; Burgard M; Lachassine E; Barret B; Chaix ML; Bongain A; Ciraru-Vigneron N; Crenn-Hébert C; Delfraissy JF; Rouzioux C; Mayaux MJ; Blanche S;
    JAMA; 2001 Apr; 285(16):2083-93. PubMed ID: 11311097
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
    Bellman PC
    AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.
    Horneff G; Adams O; Wahn V
    AIDS; 1998 Mar; 12(5):489-94. PubMed ID: 9543447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.